Clinical trials: Nervousness
Progressive Supranuclear Palsy, PSP
AMX0035 and Progressive Supranuclear Palsy
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an…
- Conditions
- Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
- Trial name
- ORION (NCT06122662)
- Testing
- AMX0035
- Where
- 62 sites in United States, France and 3 more
- Volunteers
- 139 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Narcolepsy
A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy
The purpose of this study is to investigate the efficacy and safety after administration of TS-091 compared with placebo in patients with narcolepsy.
- Trial name
- NCT03267303
- Testing
- TS-091 5mg, TS-091 10mg
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 53 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Restless Legs Syndrome (RLS)
A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
The objective of this study was to assess the efficacy of once-daily oral administration of gabapentin enacarbil versus placebo, based on the change in International Restless Legs Syndrome Rating Scale (IRLS) score in…
- Trial name
- NCT03053427
- Testing
- Gabapentin enacarbil
- Where
- 46 sites in Japan
- Volunteers
- 375 people
- Sponsor
- Astellas Pharma Inc
Insomnia
A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects
Primary Objective : To evaluate the effect of ticagrelor tablets on the pharmacokinetic characteristics of YZJ-1139 in healthy subjects; Secondary Objective: To evaluate the safety of ticagrelor tablets in combination with…
- Trial name
- NCT06671470
- Testing
- YZJ-1139 tablets, Ticagrelor Tablets
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Glycogen Storage Disease Type II, Pompe Disease
rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)
Glycogen Storage Disease Type II ("GSD-II"; also known as Pompe disease) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA).
- Conditions
- Glycogen Storage Disease Type II, Pompe Disease, Acid Maltase Deficiency Disease, Glycogenosis 2
- Trial name
- NCT00053573
- Testing
- Myozyme
- Where
- 6 sites in United States, France and 2 more
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Alzheimer's Disease
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects
The primary purpose of this study is to investigate the safety and tolerability of AZD0328 following once-daily dosing for 13 days in elderly healthy volunteers and to define maximum tolerated dose.
- Trial name
- NCT00687141
- Testing
- AZD0328
- Where
- 4 sites in Sweden
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Advanced Parkinson's Disease
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.
- Trial name
- NCT00357994
- Testing
- Levodopa carbidopa intestinal gel (LCIG), Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, CADD-Legacy® 1400 ambulatory infusion pump
- Where
- 15 sites in United States, Germany
- Volunteers
- 36 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Alzheimer's Disease, Dementia With Lewy Bodies
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.
- Conditions
- Alzheimer's Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
- Trial name
- NCT02910102
- Testing
- RVT-101 35 mg
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Axovant Sciences Ltd.
Acute Ischemic Stroke
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke).
- Trial name
- TENACITY (NCT07361302)
- Testing
- Tenecteplase, Standard of care treatment
- Where
- 257 sites in Argentina, Australia and 14 more
- Volunteers
- 1,325 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke, Intracranial Aneurysms
Intracranial Distal Access Catheter in Neurointerventional Therapy
The study objective is to evaluate the safety and effectiveness of Intracranial Distal Access Catheter in neurointerventional therapy.
- Trial name
- NCT06989931
- Testing
- Intracranial Distal Access Catheter
- Where
- 6 sites in China
- Volunteers
- 114 people
- Sponsor
- MicroPort NeuroTech Co., Ltd.
Muscular Dystrophy, Facioscapulohumeral
Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of SRP-1001 in participants with facioscapulohumeral muscular dystrophy Type 1 (FSHD1).
- Trial name
- NCT06131983
- Testing
- SRP-1001 for Injection
- Where
- 16 sites in Australia, Canada and 5 more
- Volunteers
- 60 people
- Sponsor
- Sarepta Therapeutics, Inc.
Primary Insomnia
Comparison of Two Temperatures to Treat Insomnia
Insomnia patients demonstrate subjective and physiological hyperarousal. The Cereve Sleep System has been proposed as a clinical treatment to reverse this hyperarousal in insomnia patients.
- Trial name
- NCT01790256
- Testing
- Cereve Sleep System at 30 degrees C, Cereve Sleep System at 14-16 degrees C
- Where
- 9 sites in United States
- Volunteers
- 144 people
- Sponsor
- Cereve, Inc.
Ornithine Transcarbamylase Deficiency
Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency
The objectives of the study are to characterize urea production rates in patients with OTC, characterize the association of rate of ureagenesis and disease severity in OTC patients, characterize the association of rate of…
- Trial name
- NCT04717453
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Acute Ischemic Stroke
Feasibility Study of RapidPulseTM Aspiration System as Frontline Approach for Stroke Patients
A Feasibility Study to evaluate the initial safety and performance of the RapidPulseTM Aspiration System in the treatment of patients with Acute Ischemic Stroke (AIS) due to Large Vessel Occlusion (LVO).
- Trial name
- RapidPulseFS (NCT05122637)
- Testing
- RapidPulseTM Aspiration System, Standard of Care Aspiration Thrombectomy System
- Where
- 5 sites in Brazil, Denmark and 3 more
- Volunteers
- 80 people
- Sponsor
- RapidPulse, Inc
Acromegaly
A Study to Evaluate MAR002 for Acromegaly
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly
- Trial name
- NCT07641179
- Testing
- MAR002
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Marea Therapeutics
Snoring, Obstructive Sleep Apnea
Intraoral Tongue Stimulation for Treatment of Primary Snoring
Intraoral Neuromuscular Training for Treatment of Snoring Objective Studies show that improving pharyngeal muscle tone can ameliorate obstructive sleep apnoea (OSA) and snoring.
- Trial name
- NCT03829956
- Testing
- Intraoral tongue stimulator (Snoozeal)
- Where
- United Kingdom
- Volunteers
- 115 people
- Sponsor
- Signifier Medical Technologies
Acute Ischemic Stroke
Feasibility Study of RapidPulseTM Aspiration System as Frontline Approach for Patients With Acute Ischemic Stroke
A feasibility study to evaluate the initial safety and performance of the RapidPulseTM Aspiration System in the treatment of patients with Acute Ischemic Stroke (AIS) due to Large Vessel Occlusion (LVO) in the intracranial ICA…
- Trial name
- PULSE-F (NCT05577351)
- Testing
- RapidPulseTM Aspiration System
- Where
- 2 sites in Georgia
- Volunteers
- 5 people
- Sponsor
- RapidPulse, Inc
Epilepsies, Partial
Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures
Subjects enrolled in the SP615, SP756, or SP774 open-label extension (OLE) trials receiving oral SPM 927 for at least 8 weeks and a stable dose of up to 3 antiepileptic medications may participate in a research trial at…
- Trial name
- NCT00151879
- Testing
- SPM 927
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- UCB Pharma
Advanced Solid Tumors
Phase I Trial of Oral PX-866
This study is being conducted to determine the safety and maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.
- Trial name
- NCT00726583
- Testing
- PX-866
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Cascadian Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.